A Study of LY3885125 in Participants With Dyslipidemia or Non-Alcoholic Fatty Liver Disease (NAFLD)

NCT06007651 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

49

Enrollment

INDUSTRY

Sponsor class

Stopped Participants were not dosed in Part B as per the protocol.

Conditions

Dyslipidemias
Non-Alcoholic Fatty Liver Disease

Interventions

DRUG: LY3885125
DRUG: Placebo

Sponsor

Eli Lilly and Company